Yes, although biased to see things through rose colored glasses, management’s relative restraint in a situation they wouldn’t want to face again in the not too distant future lends some support to the JV/BO rumors.
I can get behind what they are asking for. We’re probably not getting any big news before the ASM (let alone having it at Merck HQ) but the company delivered enough news to warrant a share limit authorization increase.